Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-6
(
IL-6
) is a multifunctional cytokine playing roles in the immune system, hematopoiesis, and acute phase reactions.
IL-6
also regulates the growth of various types of human malignant tumors. Here we demonstrate that
IL-6
-induced gene expression was suppressed by a specific heat-shock protein 90 (Hsp90) inhibitor, geldanamycin (GA) in human hepatoma Hep3B cells. GA also suppressed the
IL-6
-induced activation of signal transducer and activator of transcription 3 (STAT3) in a human embryonic kidney
carcinoma
293T cells. This inhibitory effect of GA on STAT3 activation was reversed by overexpression of Hsp90. Furthermore, Hsp90 directly bound to STAT3 via its N-terminal region, which interacted with GA. We provide evidence that the action of GA on
IL-6
functions was due to the inhibition of direct physical interactions between STAT3 and Hsp90, which represents a novel role of Hsp90 in the
IL-6
signaling pathways.
...
PMID:Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. 1255 50
STAT3 and STAT5 are constitutively activated and nuclear in nasopharyngeal
carcinoma
(NPC) cells. In normal signaling, STATs are only transiently activated. To investigate whether Epstein-Barr virus (EBV), and in particular the protein LMP1, contributes to sustained STAT phosphorylation and activation in epithelial cells, we examined STAT activity in two sets of paired cell lines, HeLa, an EBV-converted HeLa cell line, HeLa-Bx1, the NPC-derived cell line CNE2-LNSX, and an LMP1-expressing derivative, CNE2-LMP1. EBV infection was associated with a significant increase in the tyrosine-phosphorylated forms of STAT3 and STAT5 in HeLa-Bx1 cells. This effect correlated with LMP1 expression, since phosphorylated STAT3 and STAT5 levels were also increased in CNE2-LMP1 cells relative to the control CNE2-LNSX cells. No change was observed in STAT1 or STAT6 phosphorylation in these cell lines, nor was there a significant change in the levels of total STAT3, STAT5, STAT1, or STAT6 protein. Tyrosine phosphorylation allows the normally cytoplasmic STAT proteins to enter the nucleus and bind to their recognition sequences in responsive promoters. The ability of LMP1 to activate STAT3 was further established by immunofluorescence assays in which coexpression of LMP1 in transfected cells was sufficient to mediate nuclear relocalization of Flag-STAT3 and by an electrophoretic mobility shift assay which showed that LMP1 expression in CNE2-LNSX cells was associated with increased endogenous STAT3 DNA binding activity. In addition, the activity of a downstream target of STAT3, c-Myc, was upregulated in HeLa-Bx1 and CNE2-LMP1 cells. A linkage was established between
interleukin-6
(
IL-6
)- and LMP1-mediated STAT3 activation. Treatment with
IL-6
increased phosphorylated STAT3 levels in CNE2-LNSX cells, and conversely, treatment of CNE2-LMP1 cells with
IL-6
neutralizing antibody ablated STAT3 activation and c-Myc upregulation. The previous observation that STAT3 activated the LMP1 terminal repeat promoter in reporter assays was extended to show upregulated expression of endogenous LMP1 mRNA and protein in HeLa-Bx1 cells transfected with a constitutively activated STAT3. A model is proposed in which EBV infection of an epithelial cell containing activated STATs would permit LMP1 expression. This in turn would establish a positive feedback loop of
IL-6
-induced STAT activation, LMP1 and Qp-EBNA1 expression, and viral genome persistence.
...
PMID:A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. 1263 72
We investigated the clinical significance and regulation of serum
interleukin-6
(
IL-6
) in patients with nasopharyngeal
carcinoma
(NPC). Serum
IL-6
levels of 314 NPC patients and 202 healthy individuals were determined. Of the NPC patients, 69.1% (217/314) showed higher
IL-6
levels than that of normal average (2.76+/-2.06 pg/ml). Elevation of
IL-6
correlated with the advanced disease and the adverse prognosis of NPC patients. By employing in situ hybridization technique,
IL-6
mRNA was detected in the tumor cells of NPC patients with high serum
IL-6
levels. Concurrently, serum levels of butyrate were determined in 147 NPC patients and 52 healthy individuals by gas chromatography. Patients with elevated serum butyrate concentrations (4.2+/-2.2 micro M) also had significantly higher
IL-6
levels (29.14+/-5.17 pg/ml). No detectable serum butyrate was measured in the healthy individuals. In order to investigate the direct relationship between butyrate and
IL-6
, n-sodium butyrate (n-BT) was added to the NPC cells in an in vitro study, and marked increase of
IL-6
expression was detected in n-BT-treated cells. Our results suggested that tumor cells could be an important source of elevated serum
IL-6
in patients with NPC and that
IL-6
level in NPC patients was proportional to the serum butyrate concentration. In vitro,
IL-6
expression in NPC cells could be up-regulated by butyrate.
...
PMID:The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. 1279 28
The production of
interleukin-6
(
IL-6
) has been discovered in a variety of human tumors. Here we report the expression of
IL-6
,
IL-6
receptor alpha (IL-6Ralpha), and gp130 in human esophageal
carcinoma
tissues. We further demonstrate that
IL-6
protects an esophageal
carcinoma
cell line CE48T/VGH from apoptosis induced by staurosporine.
IL-6
stimulation induced a rapid phosphorylation of gp130 and STAT3, and a dominant-negative STAT3 completely abolished the antiapoptotic effect.
IL-6
also activated ERK 1/2 in CE48T/VGH cells. Inhibition of the ERK activation by PD98059 and transfection of a dominant-negative ERK2 completely blocked the protection of
IL-6
against apoptosis. Thus, both STAT and MAP kinase pathways are responsible for the
IL-6
-delivered survival signal in human esophageal
carcinoma
cells. In contrast, PI3-K inhibitors only partially attenuated the effect of
IL-6
, suggesting that PI3-K does not play a major role in the antiapoptotic signal of
IL-6
in our system. To investigate whether
IL-6
could induce the production of antiapoptotic molecules, proteins of the Bcl-2 family were measured. While Bcl-2, Bcl-x(L,), and Bax were not affected, Mcl-1 was induced by
IL-6
in human esophageal
carcinoma
cells. Our results suggest that
IL-6
may contribute to the progression of esophageal cancers in an autocrine or paracrine manner.
...
PMID:Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. 1458 7
Aminopeptidase N (APN)/CD13 is a transmembrane ectopeptidase expressed on a wide variety of cells. However, the precise function of APN/CD13 in tumor cells and the relationship of APN/CD13 to thyroid cancer remain unclear. In our study, we quantified the expression of APN/CD13 and additionally dipeptidyl peptidase IV (DPIV)/CD26 in thyroid
carcinoma
cell lines and in tissues of patients with thyroid carcinomas. Undifferentiated anaplastic thyroid carcinomas expressed more APN/CD13 than differentiated thyroid carcinomas. DPIV/CD26 showed an opposite expression pattern. We detected higher levels of DPIV/CD26 in follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas than in undifferentiated anaplastic thyroid carcinomas. In the undifferentiated thyroid
carcinoma
cell line 1736, APN/CD13 mRNA expression could be increased by epidermal growth factor, basic fibroblast growth factor,
interleukin-6
, and tumor necrosis factor alpha. FTC-133 cells stably transfected with an expression vector for APN-enhanced green fluorescent protein showed a higher migration rate than FTC-133 cells transfected with the enhanced green fluorescent protein-control plasmid. Overexpression of APN/CD13 in stably transfected cells is associated with down-regulation of N-myc down-regulated gene (NDRG)-1, melanoma-associated antigen ME491/CD63, and DPIV/CD26 gene expression. Inhibition of APN/CD13 mRNA expression by small interfering RNA induced NDRG-1, ME491/CD63, and DPIV/CD26 mRNA expression in cells of the undifferentiated thyroid
carcinoma
cell line C643. We conclude that APN/CD13-associated down-regulation of NDRG-1, ME491/CD63, and DPIV/CD26 in thyroid
carcinoma
cells is an important step of tumor progression to more malignant phenotypes, and we underline the important role of APN/CD13 as mediator in a multimolecular process regulating cell migration.
...
PMID:Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. 1467 16
Interleukin-6
(
IL-6
) and its receptor have been implicated in prostate cancer progression. Because other members of the
IL-6
family such as leukaemia inhibitory factor (LIF) and oncostatin M (OSM) share gp130, the signal transduction subunit of their receptors, interpretation of the data without considering the expression of these cytokines and their specific receptor subunits could be misleading. The immunohistochemical pattern of the
IL-6
family and their receptor subunits in normal prostate, benign prostatic hyperplasia (BPH), and prostatic
carcinoma
(PC) was investigated. In normal prostates, gp130 and OSMRalpha were detected exclusively in the stroma and LIFRbeta was very scarce. While
IL-6
was scarcely immunolocalized to the basal cells of the epithelium, OSM was detected in the stroma and LIF in both the epithelium and the stroma. This suggests an autocrine role for this family of cytokines in the stroma of normal prostates. In BPH, gp130 and OSMRalpha were detected both in the epithelium and in the stroma, whereas LIFRbeta was localized only to the epithelium.
IL-6
localized preferentially to the epithelium, OSM to the stroma, and LIF to both compartments. Therefore, in addition to the autocrine role in the stroma,
IL-6
and OSM may play a paracrine role from the stroma to the epithelium in BPH. In PC, gp130 and OSMRalpha were detected both in the epithelium and in the stroma, increasing with rising Gleason grade, whereas LIFRbeta was localized exclusively to the epithelium of low Gleason grade carcinomas.
IL-6
, LIF, and OSM localized in all cell types, with immunostaining increasing with Gleason grade. These data suggest an autocrine role for these cytokines in the epithelial cells of PC. The distinct pattern of expression of LIFRbeta exclusively in low Gleason grade carcinomas makes LIFRbeta a candidate for malignancy diagnosis. The role of OSM mainly in high Gleason grade carcinomas makes OSM a putative target for prostate cancer therapy.
...
PMID:Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. 1469 20
Serum and tissue levels of
interleukin-6
(
IL-6
) have been implicated in the biological phenotype of breast
carcinoma
. A common G/C polymorphism at position -174 of the
IL-6
promoter can influence the expression level of this gene. We therefore investigated for associations between this polymorphism and various phenotypic features in a series of 256 breast cancers. Individuals who were homozygous for the C allele (n=55) were more likely to have higher-grade tumours (P=0.039) with ductal histology (P=0.030) compared to those harbouring at least one wild-type G allele (n=201). Homozygosity for the C allele was also associated with significantly worse overall survival (P=0.031). We conclude that the -174 C allele of
IL-6
is associated with a more aggressive breast cancer phenotype.
...
PMID:The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. 1473 87
Interleukin-6
(
IL-6
) is a proinflammatory cytokine associated with the disease status of gastric
carcinoma
(GC). Vascular endothelial growth factor (VEGF) is a potent tumor angiogenic factor in GC. In this study, we attempted to clarify whether
IL-6
can regulate VEGF and angiogenesis in GC. GC samples from 54 surgical specimens were subjected to immunohistochemical examination of
IL-6
, VEGF, and tumor microvessels, and results showed that
IL-6
was positively correlated with VEGF expression and tumor vasculature. We determined VEGF expression in four GC cell lines by ELISA, revealing that GC cells can produce significant amount of VEGF with increasing dose and duration of
IL-6
stimulation. Next, a luciferase reporter gene assay was employed to determine the signaling pathway driving the VEGF promoter by
IL-6
, which showed that the JAK/STAT pathway is involved in the stimulation of VEGF gene expression. The effects of
IL-6
on angiogenesis in vitro and in vivo were evaluated by HUVEC studies and the Matrigel plug assay, respectively. Results showed that
IL-6
effectively promoted HUVEC proliferation and tube formation in vitro and Matrigel plug vascularization in vivo, primarily by inducing VEGF in GC. This study provides evidence that the multifunctional cytokine,
IL-6
, may induce VEGF expression which increases angiogenesis in gastric carcinogenesis.
...
PMID:Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. 1515 87
The androgen receptor co-activator CREB (cAMP-response element binding protein)-binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin-like growth factor-I or
interleukin-6
(
IL-6
). CBP protein and mRNA expression were studied by western blotting and real-time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy-resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down-regulated by R1881 or
IL-6
. The non-steroidal anti-androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of
IL-6
. In contrast, neither R1881 nor
IL-6
caused any effect on CBP expression in the PC-3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or
IL-6
was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up-regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate
carcinoma
.
...
PMID:The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. 1537 87
Multiple cytokines are secreted by Hodgkin lymphoma (HL) cells, notably
interleukin-6
(
IL6
), which is believed to play a significant pathobiological role in this and certain other tumors. Previous work on prostate
carcinoma
cells has shown that
IL6
expression is activated therein by the homeodomain protein GBX2, which we found to be absent in HL cells. Instead, we observed expression of a closely related gene, HLXB9, albeit restricted to HL cells coexpressing
IL6
. Treatment of HL cell lines with antisense-oligonucleotides directed against HLXB9, forced expression of recombinant HLXB9, and analysis of reporter gene constructs containing
IL6
promoter sequences all confirmed the potential of HLXB9 to drive expression of
IL6
. Chromosomal rearrangements of the HLXB9 locus at 7q36 were not detected in HL cells unlike AML subsets expressing HLXB9. However, inhibition of certain signal transduction pathways revealed that the phosphatidylinositol 3 kinase (PI3K) pathway contributes to HLXB9 expression. AKT/phospho-AKT analysis revealed constitutively active PI3K signalling in HL cell lines. Downstream analysis of PI3K revealed that E2F3 may mediate activation of HLXB9. Taken together, our data show that the PI3K signalling pathway in HL cells is constitutively activated and promotes HLXB9 expression, probably via E2F3, thereby enhancing malignant expression of
IL6
.
...
PMID:HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. 1577 2
<< Previous
1
2
3
4
5
6
7
8
9
10